We are live on ! Find out more

ECYT

Endocyte, Inc. Common Stock

ECYT

Delisted

ECYT was delisted on the 20th of December, 2018.

96 hedge funds and large institutions have $49.4M invested in Endocyte, Inc. Common Stock in 2016 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 28 increasing their positions, 31 reducing their positions, and 10 closing their positions.

New

Increased

Maintained

Reduced

Closed

491% more call options, than puts

Call options by funds: $260K | Put options by funds: $44K

1% less capital invested

Capital invested by funds: $49.7M → $49.4M (-$260K)

10% less repeat investments, than reductions

Existing positions increased: 28 | Existing positions reduced: 31

1% less funds holding

Funds holding: 97 → 96 (-1)

10% less first-time investments, than exits

New positions opened: 9 | Existing positions closed: 10

Holders

Holders Change

-1

Holders Change %

-1.03%

% of All Funds

2.56%

Holding in Top 10

–

Holding in Top 10 Change

–

Holding in Top 10 Change %

–

% of All Funds

–

New

Increased

Reduced

Closed

Calls

$260K

Puts

$44K

Net Calls

+$216K

Net Calls Change

+$234K

Top Buyers

Rank	Fund	Capital Flow
1	JP Morgan Chase New York	+$2.86M
2	Jacobs Levy Equity Management Florham Park, New Jersey	+$247K
3	BFA BlackRock Fund Advisors San Francisco, California	+$192K
4	Stifel Financial St. Louis, Missouri	+$145K
5	BCM Bridgeway Capital Management Houston, Texas	+$76.6K

Top Sellers

Rank	Fund	Capital Flow
1	BBA Baker Bros. Advisors New York	-$2.07M
2	Millennium Management New York	-$1.09M
3	HCMT Highland Capital Management (Texas) Dallas, Texas	-$558K
4	Fidelity Investments Boston, Massachusetts	-$412K
5	Morgan Stanley New York	-$355K

#	Name	Holding	Trade Value	Shares Change	Change in Stake
26	26 California State Teachers Retirement System (CalSTRS) West Sacramento, California	$256K	-$3.3K	-900	-1%
27	27 Ameriprise Minneapolis, Minnesota	$252K	+$48.5K	+13,245	+20%
28	28 Morgan Stanley New York	$244K	-$355K	-96,778	-56%
29	29 Goldman Sachs New York	$243K	-$195K	-53,108	-41%
30	PAM 30 Panagora Asset Management Boston, Massachusetts	$229K	+$12.1K	+3,295	+5%
31	31 Jacobs Levy Equity Management Florham Park, New Jersey	$217K	+$247K	+67,493	New
32	TA 32 Teachers Advisors New York	$179K	–	–	–
33	33 New York State Common Retirement Fund Albany, New York	$174K	–	–	–
34	CCM 34 Cribstone Capital Management Augusta, Maine	$152K	+$54.3K	+14,808	+46%
35	35 RhumbLine Advisers Boston, Massachusetts	$141K	-$54K	-14,738	-25%
36	36 State Board of Administration of Florida Retirement System Tallahassee, Florida	$139K	–	–	–
37	SIP 37 Stoneridge Investment Partners Radnor, Pennsylvania	$132K	–	–	–
38	38 Stifel Financial St. Louis, Missouri	$127K	+$145K	+39,629	New
39	39 ProShare Advisors Bethesda, Maryland	$116K	+$2.14K	+585	+2%
40	NFA 40 Nationwide Fund Advisors Columbus, Ohio	$107K	+$29.3K	+7,989	+31%
41	1SB 41 1ST Source Bank South Bend, Indiana	$106K	–	–	–
42	CP 42 Corbenic Partners Bethlehem, Pennsylvania	$105K	+$7.33K	+2,000	+7%
43	43 Dimensional Fund Advisors Austin, Texas	$99K	–	–	–
44	SCM 44 Sterling Capital Management Charlotte, North Carolina	$98K	–	–	–
45	ARTA 45 A.R.T. Advisors New York	$97K	-$233K	-63,700	-68%
46	WS 46 Wedbush Securities Los Angeles, California	$97K	–	–	–
47	LCM 47 Leisure Capital Management Costa Mesa, California	$95K	+$70	+19	+0.1%
48	PP 48 PDT Partners New York	$88K	-$4.03K	-1,100	-4%
49	CS 49 Credit Suisse Zurich, Switzerland	$84K	+$6.69K	+1,826	+7%
50	VKH 50 Virtu KCG Holdings New York	$84K	+$40.6K	+11,081	+73%

ECYT Hedge Fund Activity: Q2 2016 in Review

96 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Endocyte, Inc. Common Stock (ECYT) for Q2 2016, worth a combined $49.4M — down 0.52% from $49.7M a quarter earlier.

Sellers outnumbered buyers: 10 funds closed out of ECYT and 9 opened new positions — a net loss of 1 holder — while 31 trimmed existing stakes and 28 added.

The largest buyer was JP Morgan Chase, adding an estimated $2.86M. The largest seller was Baker Bros. Advisors, cutting an estimated $2.07M.

96 institutional investors held Endocyte, Inc. Common Stock (ECYT) as of Q2 2016, down from 97 in Q1 2016.
Funds reported $49.4M of Endocyte, Inc. Common Stock stock for Q2 2016, down 0.52% quarter-over-quarter.
9 funds opened new Endocyte, Inc. Common Stock positions in Q2 2016 and 10 closed out, a net change of -1 holder.
The largest Endocyte, Inc. Common Stock buyer in Q2 2016 was JP Morgan Chase, an estimated $2.86M added.
The largest Endocyte, Inc. Common Stock seller in Q2 2016 was Baker Bros. Advisors, an estimated $2.07M sold.

Based on aggregated 13F filings for Q2 2016.

Endocyte, Inc. Common Stock ECYT